This document discusses direct oral anticoagulants (DOACs) for treating and preventing blood clots. It summarizes clinical trials that found DOACs like dabigatran, rivaroxaban, apixaban, and edoxaban were as effective or more effective than warfarin for reducing strokes in atrial fibrillation while causing less bleeding. The document outlines the targets, dosing, monitoring requirements, and indications for each DOAC. It also notes advantages like fixed dosing and no monitoring required with DOACs, but potential disadvantages include lack of antidotes and methods to assess patient adherence.